U.S. HIV vaccine trial ends in failure


U.S. authorities announced Thursday they have halted clinical trials of an experimental vaccine designed to halt the HIV virus after discovering it did not stop infection.

The program, which began in 2009, is the latest in a series of unsuccessful studies of candidate vaccines aimed at HIV.

The National Institute of Allergy and Infectious Diseases said volunteers in 19 U.S. cities — either gay men or transgender people who had sex with men — took part in the study, with the HVTN 505 vaccine given to 1,250 and the other 1,244 receiving a placebo.

A panel analyzed the results of the study Monday and recommended halting the program after findings indicated 41 infections among those who had received the vaccine versus 30 in the placebo group. The institute plans to continue to follow the participants to further analyze the results of the study.